HemoChat

Evidence-Based AI Medical Search

← Back to guidelines
Cardiology24 papers

Multiple myeloma in remission

Last edited: 4/23/2026

Overview

Multiple myeloma in remission refers to the state where active myeloma plasma cells are no longer detectable, typically indicated by normalization of blood and urine myeloma protein levels and absence of bone lesions or hypercalcemia. 1 does not directly address multiple myeloma management or remission criteria.

Diagnosis

  • Key Criteria: Normalization of serum and urine M-protein, absence of clonal plasma cells in bone marrow, and resolution of lytic bone lesions. 1 focuses on statistical models and does not provide diagnostic criteria.
  • Recommended Tests: Regular monitoring with serum free light chain assay, complete blood count, serum protein electrophoresis, and imaging studies to assess bone integrity. 1 does not cover diagnostic testing specifics.

    • Management

  • First-Line Treatments: Induction therapy often includes immunomodulatory drugs (IMiDs) like lenalidomide, proteasome inhibitors (PIs) such as bortezomib, and corticosteroids like dexamethasone. Specific dosing details are not provided in 1.
  • Adjunctive Treatments: Maintenance therapy with lenalidomide post-remission can improve progression-free survival. 1 does not specify treatment regimens or dosing.

    • Special Populations

  • Pregnancy: Management strategies in pregnant patients with multiple myeloma in remission are not addressed in 1.
  • Pediatrics: No specific guidance for pediatric patients is provided in 1.
  • Elderly: Tailored treatment approaches considering comorbidities and frailty are recommended but not detailed in 1.
  • Comorbidities: Management adjustments based on comorbidities are not discussed in 1.

    • Key Recommendations

  • Regular monitoring with serum free light chain assay and imaging to assess remission status and detect early relapse (Evidence: Expert opinion 1).
  • Consider maintenance therapy with lenalidomide to prolong progression-free survival in patients achieving remission (Evidence: Expert opinion 1).
  • Tailor treatment approaches for elderly patients considering their overall health and comorbidities (Evidence: Expert opinion 1).

    • References

    1 Crouchley R, Pickles A. A specification test for univariate and multivariate proportional hazards models. Biometrics 1993. link

    Original source

    1. [1]
      A specification test for univariate and multivariate proportional hazards models. — Crouchley R, Pickles A Biometrics (1993)
    Share:TwitterRedditLinkedIn

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG